# Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

> **NCT06613633** · — · COMPLETED · sponsor: **Fudan University** · enrollment: 4000 (actual)

## Conditions studied

- Third-generation TKI
- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

## Key facts

- **NCT ID:** NCT06613633
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2026-02-20
- **Target enrollment:** 4000 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613633, "Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06613633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*